P251 Proactive Therapeutic drug monitoring of Infliximab, but not HLA-DQA1*05, predicts clinical outcome in inflammatory bowel disease
I Alonso,M Carrillo Palau,B Vera,M Vela,A Morant,L Ramos,C Reygosa,J S Medina Chico,Y Barrios,A Franco,F Gutiérrez-Nicolás,A Jiménez,M Hernández-Guerra
DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0381
2024-01-01
Journal of Crohn's and Colitis
Abstract:Abstract Background While anti-TNF drugs effectively manage Inflammatory Bowel Disease (IBD), treatment failure rates exceed 40%. Monitoring drug levels, antibodies (Abs), and HLA-DQA1*05 allele typing could optimize patient care. The aim of this study is to evaluate the clinical impact of Infliximab (IFX) and Abs monitoring in IBD patients and to understand the influence of the HLA-DQA1*05 allele on IFX treatment response and maintenance. Methods We conducted a multicenter, observational study involving patients initiating IFX treatment between October 2020 and October 2022. Demographic, clinical, analytical, and endoscopic data, along with disease activity indicators, were prospectively collected. IFX and Abs levels were measured at weeks 6, 14, 30, and 12 months. HLA-DQA1*05 genotyping was performed at baseline. Statistical tests assessed correlations between IFX levels and disease activity. Results Ninety-three IBD patients (45±17 years, 46% female) initiated IFX treatment, mostly anti-TNF naïve (90%). At baseline, 91% had an active disease (GPA = 1) and 85,7% a FC > 150 mg/kg. PRO at baseline was 59.22±8.72. Median follow up was 15 months. HLA was determined in 91 patients, of whom 35 (38.5%) where HLA-DQA1*05 positive. IFX levels > 7 μg/mL correlated with improved disease outcomes in week 6, 14 and 30. In this way, IFX levels > 7 μg/mL in week 6 were associated with CRP < 5 mg/L (p = 0.008), FC <150 mg/kg (p = 0.011) and GPA = 0 (p = 0.0016) in week 6 and with GPA = 0 (p = 0.042) in week 14. IFX levels > 7 μg/mL in week 14 were associated with GPA = 0 (p = 0,001) and FC <150 mg/kg (p = 0,0015) in week 14 and with GPA = 0 (p = 0,019) and FC <150 mg/ kg (p = 0,027) in week 30. IFX levels > 3 μg/mL at 12 months follow-up were associated with FC < 150 mg/kg (p = 0,001). PRO was used to evaluate patients’evolution, and progressive improvement in scores at weeks 0, 14 and 30 was observed (p > 0.001). IFX levels > 7 μg/mL at week 14 were associated with a better PRO score at week 14. Discontinuation (40%) within the first year linked to higher CRP and FC at week 0 and active disease at weeks 6, 14, and 30. Conclusion Early IFX monitoring at weeks 6 and 14 optimizes IBD management. IFX levels > 7 μg/mL indicate better short and long-term clinical outcomes and drug durability, irrespective of HLA-QDA1*05 status.
gastroenterology & hepatology